Clinical Trial

FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study

Study acronym: FESTIVAL
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota. Translated with DeepL.com (free version)
Trial Details
NCT Number NCT07668713
Lead Sponsor University Hospital, Clermont-Ferrand
Conditions Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT)
Enrollment 24 participants
Start Date 2026-06-01
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-25